Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Gene Therapy

Exploring and comparing the curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL

The treatment and management of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) remains a major unmet need, and in recent…

Date: 23rd August 2023

Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma

Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory…

Date: 3rd August 2023

Overcoming barriers to CAR-T therapy: improving access and cost

CAR-T therapy has become a promising novel option for patients with relapsed/refractory (R/R) hematological malignancies, providing hope to several individuals…

Date: 27th July 2023

Updates in the treatment and management of amyloidosis and the importance of the multidisciplinary team

Amyloidosis is a rare disease in which insoluble amyloid proteins are deposited in tissues or organs, resulting in organ damage….

Date: 11th July 2023

Hemophilia: the current standard of care and the value of novel gene therapies

Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of…

Date: 5th July 2023

Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice

In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients…

Date: 22nd June 2023

Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management

The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and…

Date: 16th June 2023

iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…

Date: 7th June 2023

iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…

Date: 24th May 2023

iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…

Date: 18th May 2023

iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies

The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…

Date: 11th May 2023

iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed

The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…

Date: 2nd May 2023